Does taking nicotinamide riboside (NR) improve health?

NR belongs to a family of NAD+ precursors that includes niacin (vitamin B3), nicotinamide (NAM), and nicotinamide mononucleotide (NMN). What distinguishes NR is where it enters the biosynthetic pathway: it is converted directly to NMN inside cells, then to NAD+ — bypassing several rate-limiting steps that slow conversion from niacin or nicotinamide¹.

The NAD+ problem with aging is well documented. Studies in humans and animals consistently show that NAD+ levels in muscle, skin, and blood fall by 40–60% between early adulthood and middle age. This decline reflects both slowing synthesis and faster consumption by inflammatory enzymes — particularly CD38, which accumulates with chronic low-grade inflammation as we age. Restoring NAD+ is hypothesized to support mitochondrial energy production, sirtuin enzyme activity (which regulates cellular repair and stress responses), and PARP enzymes that fix DNA strand breaks.

Bioavailability. The foundational human study showed that a single oral dose of NR raises blood NAD+ metabolites in a dose-dependent manner — demonstrating that NR survives digestion and is absorbed intact through the gut¹. This was an important finding because earlier debate existed about whether orally administered NAD+ precursors could survive the digestive tract.

What the Science Shows

NAD+ elevation. This is the most consistent finding across human trials. Multiple studies show that NR at doses of 250–2,000 mg/day reliably raises blood NAD+ metabolites, including NAM (nicotinamide), NAAD (nicotinic acid adenine dinucleotide), and MeNAM (methyl-NAM), within days of starting supplementation^1,2,3. The effect is dose-dependent and sustained with ongoing use.

Cardiovascular and blood pressure support. A crossover RCT in 24 healthy adults aged 55–79 found that 1,000 mg/day NR (500 mg twice daily) for 6 weeks elevated blood NAD+ metabolites by approximately 60% above placebo levels². Exploratory analysis showed systolic blood pressure trends lower in the NR group, an effect the research team has followed up with subsequent targeted trials. While not the primary outcome, these cardiovascular signals have generated significant research interest.

Neurological applications. The NADPARK trial — a randomized phase I study in 30 people with early Parkinson's disease — showed that 1,000 mg/day NR for 30 days significantly increased cerebral NAD+ levels, measured by 31P MRS brain imaging⁴. Brain metabolic activity patterns also shifted in NR-treated participants. While this was a safety/pharmacokinetics trial not powered for clinical outcomes, the finding that oral NR can cross the blood-brain barrier and raise central nervous system NAD+ is significant for research into neurodegenerative diseases.

Metabolic effects in obesity. A 12-week RCT in 40 obese men using a high dose of 2,000 mg/day NR found that blood NAD+ metabolites rose substantially, and body composition (lower fat mass, higher lean mass) shifted modestly in the NR group³. However, insulin sensitivity and primary metabolic measures did not improve significantly, suggesting that NAD+ restoration alone may not overcome the metabolic dysfunction of obesity without accompanying lifestyle changes.

NR vs. NMN: Choosing a NAD+ Precursor

NR and NMN are the two most popular NAD+ precursors, and they are closely related — NR is converted to NMN inside cells before being used to make NAD+. Key differences:

• Pathway. NMN is one step closer to NAD+. NR needs one extra enzymatic step (phosphorylation to NMN) inside cells.
• Research history. NR has a slightly longer human clinical trial record; NMN trials have accelerated since 2020.
• Cost. NR supplements are typically less expensive than NMN.
• Dosing. Human trials for NR have used 250–2,000 mg/day; NMN trials most often use 250–600 mg/day.

Both precursors reliably raise blood NAD+ metabolites in humans. The honest answer from current evidence is that no head-to-head trial in humans has established superiority of one over the other for any clinical outcome⁵. Choice often comes down to cost, availability, and individual response.

Practical Guidance

Dosage. Most human trials have used 300–1,000 mg/day. The crossover RCT showing cardiovascular trends used 1,000 mg/day². A dose of 300–500 mg/day represents a reasonable starting point. The Parkinson's trial used 1,000 mg/day with good tolerability⁴.

Timing. NAD+ is involved in circadian rhythm regulation, so many people take NR in the morning. Food does not appear to significantly affect absorption.

Safety. In the human trials described here, NR was well tolerated at doses up to 2,000 mg/day^2,3,4, and no serious adverse events due to NR were observed in the 12-week trial at that dose³. Some people report mild flushing or GI discomfort at higher doses — unlike niacin, NR does not typically cause the pronounced skin flushing associated with high-dose niacin⁵.

Food sources. NR is found naturally in cow's milk, yeast, and some vegetables, but dietary amounts are negligible compared to supplemental doses. Supplementation is the only practical way to achieve NAD+-raising levels.

See our NMN page for the related NAD+ precursor, and our mitochondrial health page for broader context on cellular energy support.

Foundational Bioavailability Study (Trammell et al., 2016)

Published in Nature Communications, this was the first study to rigorously demonstrate oral bioavailability of NR in humans¹. In a crossover design, healthy adults received single doses of NR and had blood and urine collected over 9 hours. NAD+ metabolites — including NAD+, NAAD, ADPR, and methylated NAM metabolites — rose significantly in blood and urine following NR ingestion compared to vehicle control. The study also demonstrated that NR, unlike NAM or niacin, does not rely on hepatic conversion before reaching the bloodstream, raising the possibility of more direct tissue delivery. This study established the pharmacokinetic foundation for subsequent chronic dosing trials. Key limitation: single-dose design with a small human cohort; full chronic dosing effects were not assessed.

Crossover RCT in Healthy Older Adults (Martens et al., 2018)

This randomized, double-blind, placebo-controlled crossover trial enrolled 24 healthy adults aged 55–79 years². Participants received 1,000 mg/day NR (500 mg twice daily as NIAGEN®) or placebo for 6 weeks, then crossed over after a washout period. Primary outcomes were whole-blood NAD+ metabolites; secondary outcomes included blood pressure, arterial stiffness, and markers of systemic inflammation. Results: whole-blood NAD+ metabolites rose by approximately 60% in the NR phase compared to placebo (p<0.001). Systolic blood pressure was 3.9 mmHg lower in the NR phase (p<0.05 in a subset of participants with elevated blood pressure at baseline). Pulse wave velocity, a measure of arterial stiffness, showed a non-significant trend toward improvement. No adverse events occurred. This remains one of the most important NR RCTs because of its rigorous crossover design, clean safety data, and the cardiovascular signal it generated in an older adult population.

Obese Men RCT (Dollerup et al., 2018)

This 12-week, randomized, double-blind, placebo-controlled trial enrolled 40 obese but otherwise healthy men (BMI 28–40)³. Participants received 2,000 mg/day NR or placebo. Primary outcomes were insulin sensitivity (hyperinsulinemic-euglycemic clamp) and whole-body glucose metabolism. Secondary outcomes included body composition (MRI), skeletal muscle mitochondrial function, and blood lipids. Key findings: blood NAD+ metabolites rose substantially in the NR group (whole-blood NAM increased ~50%). Body composition analysis showed a trend toward lower fat mass and higher lean mass in the NR group at 12 weeks, though this did not reach statistical significance for the primary MRI-based lean mass measure. Critically, NR did not improve insulin sensitivity or glucose metabolism compared to placebo. Lipid profiles were similar between groups. No serious adverse events occurred, confirming tolerability at 2,000 mg/day — the highest dose tested in a controlled chronic human trial. The negative metabolic findings suggest that NAD+ repletion alone may be insufficient to reverse obesity-associated insulin resistance, an important calibration of expectations for this supplement.

NADPARK Parkinson's Disease Trial (Brakedal et al., 2022)

This randomized, double-blind, phase I trial enrolled 30 people with early-stage Parkinson's disease who were not yet on dopaminergic therapy⁴. Participants received either 1,000 mg/day NR or placebo for 30 days. The primary outcome was cerebral NAD+ concentration measured by 31-phosphorus magnetic resonance spectroscopy (31P MRS) — a non-invasive method for imaging brain metabolism. Secondary outcomes included mitochondrial function markers and clinical Parkinson's disease rating scales. Results: cerebral NAD+ rose significantly in the NR group compared to placebo (mean increase ~%10, p<0.05). Cerebrospinal fluid analysis confirmed NR metabolites reached the CNS. Metabolomic analysis of CSF and blood revealed changes in TCA cycle intermediates and one-carbon metabolism pathways consistent with improved mitochondrial function in the NR group. Motor outcomes on the UPDRS scale were not significantly different at 30 days — an expected finding given the short duration and early disease stage. No serious adverse events occurred. This trial is notable as the first to demonstrate that orally administered NR can raise NAD+ in the living human brain, establishing proof of concept for NAD+ repletion as a neurological intervention. Larger trials with longer duration are underway.

Critical Evidence Review (Damgaard and Treebak, 2023)

This review critically assessed the 25 published research articles on human NR supplementation⁵, aiming to identify poorly founded claims and clarify the actual future potential of NR. Key conclusions: (1) Collectively, oral NR supplementation has displayed few clinically relevant effects. (2) There is an unfortunate tendency in the literature to exaggerate the importance and robustness of reported effects. (3) Even so, NR may play a role in the reduction of inflammatory states and has shown some potential in the treatment of diverse severe diseases. This honest assessment is important context for interpreting the enthusiasm around NR: the clinical health consequences of NAD+ repletion in humans remain an active area of investigation.

Overall Evidence Assessment

NR has one of the cleaner evidence profiles among longevity-focused supplements: oral bioavailability is confirmed, NAD+ elevation is consistent and dose-dependent, and safety across multiple controlled trials is excellent. The open questions are clinical: does reliably raising blood NAD+ translate to meaningful improvements in cardiovascular function, neurological health, or metabolic outcomes? Early signals from the Martens 2018 blood pressure data and the Brakedal 2022 brain NAD+ data are genuinely interesting, but neither trial was powered to definitively answer its secondary questions. For healthy middle-aged to older adults seeking to support mitochondrial and cellular health as part of a broader longevity strategy, the risk-benefit calculation for NR is favorable — with the honest caveat that the long-term clinical benefits in humans are still being established.